Sapienza Lucas Gomes, Ning Matthew S, de la Pena Rosinda, McNew Laura Kollar, Jhingran Anuja, Georgeon Larissa, Rasool Nabila, Gomes Maria José Leite, Abu-Isa Eyad, Baiocchi Glauco
Radiation Oncology, Baylor College of Medicine, Houston, Texas, USA
Internal Medicine, Ascension Providence Hospital, Southfield, Michigan, USA.
Int J Gynecol Cancer. 2020 Oct;30(10):1535-1541. doi: 10.1136/ijgc-2020-001281. Epub 2020 May 5.
Studies of salvage radiotherapy in locally recurrent endometrial cancer remain limited. The aim of this study was to evaluate the efficacy of salvage radiotherapy for vaginal relapse of endometrial cancer and to explore prognostic factors associated with outcomes.
We evaluated 30 patients treated with salvage external-beam radiotherapy and/or vaginal brachytherapy for vaginal relapses of endometrial cancer between 2009 and 2018. The inclusion criteria were: pathologically-confirmed recurrence; loco-regional relapse (in absence of distant metastases); and salvage treatment including external-beam radiotherapy and/or vaginal brachytherapy. Outcomes were evaluated via Kaplan-Meier, with the log-rank test employed to compare differences among various groups and identify prognostic factors.
30 patients developed vaginal recurrence at a median time of 20.6 months (range 2-219) post-hysterectomy. The most common site of recurrence was the vaginal apex (60%), followed by the distal vagina (10%). Salvage radiotherapy entailed combination external-beam radiotherapy and vaginal brachytherapy (n=24) or single modality treatment (n=6), along with concurrent chemotherapy in 20 cases. At a median follow-up of 4.4 years (range 0.1-130) post-radiotherapy, the 5 year rates of local control, regional control, metastasis-free interval, disease-free interval, and overall survival were 89%, 91.5%, 75.5%, 69%, and 83%, respectively. Factors associated with improved disease-free interval included: endometrioid histology (p=0.03), isolated vaginal relapse (p=0.003), late recurrence (>9 months) (p=0.007), and combined modality radiotherapy (p=0.001). The only factor associated with overall survival was isolated vaginal relapse (in the absence of other recurrent disease) (p=0.02). Regarding toxicity, 18% of patients experienced acute grade ≥3 events (most commonly gastrointestinal). The 5 year rates of rectal bleeding, small bowel obstruction, and pelvic fracture were 31%, 18%, and 13%, respectively.
Salvage radiotherapy imparts excellent loco-regional control for vaginal relapses of endometrial cancer and should entail combination external-beam radiotherapy and vaginal brachytherapy. Patients should be closely monitored for late gastrointestinal toxicity following salvage radiotherapy.
局部复发性子宫内膜癌挽救性放疗的研究仍然有限。本研究的目的是评估子宫内膜癌阴道复发的挽救性放疗疗效,并探索与预后相关的因素。
我们评估了2009年至2018年间接受挽救性外照射放疗和/或阴道近距离放疗治疗子宫内膜癌阴道复发的30例患者。纳入标准为:病理确诊复发;局部区域复发(无远处转移);以及包括外照射放疗和/或阴道近距离放疗的挽救性治疗。通过Kaplan-Meier评估结局,采用对数秩检验比较各组间差异并确定预后因素。
30例患者在子宫切除术后中位20.6个月(范围2-219个月)出现阴道复发。最常见的复发部位是阴道顶端(60%),其次是阴道远端(10%)。挽救性放疗包括外照射放疗与阴道近距离放疗联合(n=24)或单一模式治疗(n=6),20例患者同时接受化疗。放疗后中位随访4.4年(范围0.1-130个月),局部控制、区域控制、无转移间期、无病间期和总生存的5年率分别为89%、91.5%、75.5%、69%和83%。与无病间期改善相关的因素包括:子宫内膜样组织学(p=0.03)、孤立性阴道复发(p=0.003)、晚期复发(>9个月)(p=0.007)和联合模式放疗(p=0.001)。与总生存相关的唯一因素是孤立性阴道复发(无其他复发性疾病)(p=0.02)。关于毒性,18%的患者经历了急性≥3级事件(最常见为胃肠道事件)。直肠出血、小肠梗阻和骨盆骨折的5年发生率分别为31%、18%和13%。
挽救性放疗对子宫内膜癌阴道复发具有良好的局部区域控制效果,应采用外照射放疗与阴道近距离放疗联合。挽救性放疗后应密切监测患者的晚期胃肠道毒性。